Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

1.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Hybridoma Technology01:31

Hybridoma Technology

18.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance).

Blood advances·2026
Same author

Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia.

JCO oncology practice·2025
Same author

HoxBlinc lncRNA reprograms CTCF-independent TADs to drive leukemic transcription and HSC dysregulation in NUP98-rearranged leukemia.

The Journal of clinical investigation·2025
Same author

Sensitivity and Specificity of Chimerism Tests in Predicting Leukemia Relapse Using Increasing Mixed Chimerism.

The Journal of molecular diagnostics : JMD·2024
Same author

From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.

Cancers·2024
Same author

Recurrent disease after a matched sibling hematopoietic transplant in an aplastic anemia patient with a disease risk allele, HLA-B*40:02.

Blood transfusion = Trasfusione del sangue·2024

Related Experiment Video

Updated: Feb 25, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Autologous immunotherapy for human leukemias.

David Claxton1, Shing Fen Kao

  • 1Division of Hematology/Oncology, Department of Medicine, Penn State College of Medicine, P. O. Box 850; HO46, Hershey, PA 17033, USA. dclaxton@psu.edu

Blood Cells, Molecules & Diseases
|July 10, 2003
PubMed
Summary

Dendritic cells derived from leukemia cells can be effective in antigen presentation for immunotherapy. These leukemia-derived dendritic cells show promise as vaccines for treating acute leukemias.

More Related Videos

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Related Experiment Videos

Last Updated: Feb 25, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL
07:18

HLA-Ig Based Artificial Antigen Presenting Cells for Efficient ex vivo Expansion of Human CTL

Published on: April 11, 2011

15.9K
Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
11:55

Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade

Published on: March 14, 2011

15.0K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Immunotherapy offers potential for long-term control and cure of human leukemias.
  • Dendritic cells are crucial for effective antigen presentation in initiating immune responses.

Purpose of the Study:

  • To investigate the potential of differentiating leukemia cells into functional dendritic cells for immunotherapy.
  • To identify key factors for optimal dendritic cell differentiation from leukemia cells.

Main Methods:

  • Inducing differentiation of acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) cells into dendritic cells.
  • Utilizing cytokines like interleukin-4 (IL-4) and CD40 ligand, along with granulocyte-monocyte colony-stimulating factor (GM-CSF).

Main Results:

  • Cells from most adult AML cases successfully differentiated into effective antigen-presenting dendritic cells.
  • Optimal differentiation and maturation of dendritic cells required IL-4 and CD40 ligand.
  • Combination of GM-CSF, IL-4, and CD40 ligand yielded dendritic cells from some ALL cases.
  • Leukemia-derived dendritic cells may serve as potent vaccines for acute leukemias.

Conclusions:

  • Leukemia cells can be differentiated into functional dendritic cells, offering a novel approach to leukemia immunotherapy.
  • Further research into identifying target antigens and cloning autologous effector cells will advance antileukemic immunity protocols.
  • Clinical-scale differentiation of leukemia-derived dendritic cells could provide a viable vaccine strategy for acute leukemias.